{
    "address": "c/o Mazars SET Revisionsbyra AB, Box 159",
    "city": "Landskrona",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W9730E102",
    "description": "2cureX AB engages in the research and development of anti-cancer treatments. The company is headquartered in Landskrona, Skane. The company went IPO on 2017-11-24. The firm focuses on the research and development of diagnostic substances to select treatment for cancer patients. The firm's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The firm's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. The company operates through 2cureX A/S.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Health Care",
    "ggroup": "Health Care Equipment & Services",
    "gind": "Health Care Equipment & Supplies",
    "gsector": "Health Care",
    "gsubind": "Health Care Equipment",
    "ipo": "2017-11-24",
    "isin": "SE0010468124",
    "logo": "https://finnhub.io/api/logo?symbol=2CUREX.ST",
    "marketCapitalization": 225.6592,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "2cureX AB",
    "phone": "",
    "sedol": "BF41RR9",
    "shareOutstanding": 14.8566,
    "state": "SKANE",
    "ticker": "2CUREX.ST",
    "weburl": "https://www.2curex.com/"
}